BRIEF-Abbvie initiates phase 2 clinical trial programs for ABBV-8e12

* Abbvie initiates phase 2 clinical trial programs for

ABBV-8e12, an investigational anti-tau antibody, in early

alzheimer's disease and progressive supranuclear palsy

Source text for Eikon:...

Read more